Literature DB >> 22930390

Remodelling and adverse remodelling in CAD.

S Brenner1, G Ertl.   

Abstract

Remodelling is the adaptive or maladaptive response to cardiac overload or injury resulting in changes of size and function of the heart. The final pathway of maladaptive or adverse cardiac remodelling is the evolution of heart failure or sudden cardiac death. In coronary artery disease, ischemic injury leads to changes in the cellular and extra-cellular architecture of the infarcted and non-infarcted region resulting in cavity enlargement and loss of contractility of the entire heart. During the last three decades, potential therapeutic concepts have been established and reversal of adverse remodelling could be demonstrated in up-to end-stage disease. A further understanding of the underlying cellular, extracellular, molecular and genetic alterations in ischemic remodelling should reveal other promising targets for prevention and reversal of remodelling.

Entities:  

Mesh:

Year:  2012        PMID: 22930390     DOI: 10.1007/s00059-012-3660-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  110 in total

1.  Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

Authors:  Michael P Hudson; Paul W Armstrong; Witold Ruzyllo; Jose Brum; Lisa Cusmano; Piotr Krzeski; Robert Lyon; Miguel Quinones; Pierre Theroux; Diana Sydlowski; Henry E Kim; Mario J Garcia; Wael A Jaber; W Douglas Weaver
Journal:  J Am Coll Cardiol       Date:  2006-06-21       Impact factor: 24.094

2.  Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.

Authors:  Matthias Nahrendorf; Kai Hu; Stefan Frantz; Farouc A Jaffer; Ching-Hsuan Tung; Karl-Heinz Hiller; Sabine Voll; Peter Nordbeck; David Sosnovik; Stefan Gattenlöhner; Mikhail Novikov; Gerhard Dickneite; Guy L Reed; Peter Jakob; Anthony Rosenzweig; Wolfgang R Bauer; Ralph Weissleder; Georg Ertl
Journal:  Circulation       Date:  2006-02-27       Impact factor: 29.690

3.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

4.  Survival with congenital heart disease and need for follow up in adult life.

Authors:  C Wren; J J O'Sullivan
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

5.  L-arginine limits myocardial cell death secondary to hypoxia-reoxygenation by a cGMP-dependent mechanism.

Authors:  L Agulló; D García-Dorado; J Inserte; A Paniagua; P Pyrhonen; J Llevadot; J Soler-Soler
Journal:  Am J Physiol       Date:  1999-05

6.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

7.  Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Nikos Werner; Jürgen Haase; Jörg Neuzner; Alfried Germing; Bernd Mark; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Eur Heart J       Date:  2006-11-10       Impact factor: 29.983

8.  Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury.

Authors:  Steven P Jones; James J M Greer; Aman K Kakkar; P Derek Ware; Richard H Turnage; Michael Hicks; Rien van Haperen; Rini de Crom; Seinosuke Kawashima; Mitsuhiro Yokoyama; David J Lefer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09-11       Impact factor: 4.733

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 10.  Post-infarct remodelling: contribution of wound healing and inflammation.

Authors:  Stefan Frantz; Johann Bauersachs; Georg Ertl
Journal:  Cardiovasc Res       Date:  2008-10-31       Impact factor: 10.787

View more
  2 in total

1.  Nothing new in heart failure? A current misconception!

Authors:  B Maisch
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

2.  Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial.

Authors:  Andrew Peter Vanezis; Jayanth Ranjit Arnold; Glenn Rodrigo; Florence Y Lai; Radek Debiec; Sheraz Nazir; Jamal Nasir Khan; Leong L Ng; Kamal Chitkara; John G Coghlan; Simon Lee Hetherington; Gerry P McCann; Nilesh J Samani
Journal:  Heart       Date:  2018-05-10       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.